The global burden of group A streptococcal diseases

The global burden of disease caused by group A streptococcus (GAS) is not known. We review recent population-based data to estimate the burden of GAS diseases and highlight deficiencies in the available data. We estimate that there are at least 517 000 deaths each year due to severe GAS diseases (eg...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:The Lancet infectious diseases Jg. 5; H. 11; S. 685 - 694
Hauptverfasser: Carapetis, Jonathan R, Steer, Andrew C, Mulholland, E Kim, Weber, Martin
Format: Journal Article
Sprache:Englisch
Veröffentlicht: London Elsevier Ltd 01.11.2005
Lancet Publishing Group
Elsevier Limited
Schlagworte:
Bacterial diseases
Biological and medical sciences
Cardiovascular diseases
Developing countries
Glomerulonephritis - epidemiology
Glomerulonephritis - microbiology
Glomerulonephritis - mortality
Human bacterial diseases
Humans
Incidence
Infectious diseases
LDCs
Medical sciences
Pharyngitis - epidemiology
Pharyngitis - microbiology
Prevalence
Pyoderma - epidemiology
Pyoderma - microbiology
Rheumatic Fever - epidemiology
Rheumatic Fever - microbiology
Rheumatic Heart Disease - epidemiology
Rheumatic Heart Disease - microbiology
Sepsis - epidemiology
Sepsis - microbiology
Staphylococcal infections, streptococcal infections, pneumococcal infections
Streptococcal Infections - epidemiology
Streptococcal Infections - microbiology
Streptococcus pyogenes
Infection
Streptococcaceae
Streptococcal infection
Streptococcus A
Bacteriosis
Bacteria
Micrococcales
ISSN:1473-3099, 1474-4457
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:The global burden of disease caused by group A streptococcus (GAS) is not known. We review recent population-based data to estimate the burden of GAS diseases and highlight deficiencies in the available data. We estimate that there are at least 517 000 deaths each year due to severe GAS diseases (eg, acute rheumatic fever, rheumatic heart disease, post-streptococcal glomerulonephritis, and invasive infections). The prevalence of severe GAS disease is at least 18·1 million cases, with 1·78 million new cases each year. The greatest burden is due to rheumatic heart disease, with a prevalence of at least 15·6 million cases, with 282 000 new cases and 233 000 deaths each year. The burden of invasive GAS diseases is unexpectedly high, with at least 663 000 new cases and 163 000 deaths each year. In addition, there are more than 111 million prevalent cases of GAS pyoderma, and over 616 million incident cases per year of GAS pharyngitis. Epidemiological data from developing countries for most diseases is poor. On a global scale, GAS is an important cause of morbidity and mortality. These data emphasise the need to reinforce current control strategies, develop new primary prevention strategies, and collect better data from developing countries.
Bibliographie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
ObjectType-Review-3
content type line 23
ISSN:1473-3099
1474-4457
DOI:10.1016/S1473-3099(05)70267-X